Ion Therapy Patient Registry (REGI-MA-002015)
A Prospective Registry Study to Record Clinical Results and Side Effects of Ion Beam Therapy at MedAustron
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yvonne Goy, MD
- Phone Number: 407 +43 2622 26 100
- Email: yvonne.goy@medaustron.at
Study Contact Backup
- Name: Piero Fossati, MD MSc
- Phone Number: 408 +43 2622 26 100
- Email: piero.fossati@medaustron.at
Study Locations
-
-
Lower Austria
-
Wiener Neustadt, Lower Austria, Austria, 2700
- Recruiting
- EBG MedAustron GmbH
-
Contact:
- Yvonne Goy, MD
- Phone Number: 407 +43 2622 26 100
- Email: yvonne.goy@medaustron.at
-
Contact:
- Piero Fossati, MD MSc
- Phone Number: 408 +43 2622 26 100
- Email: piero.fossati@medaustron.at
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with tumor disease treated with ion beam therapy at MedAustron
- Signed informed consent form
Exclusion Criteria:
- Comorbidities endangering treatment delivery or study compliance
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Ion beam therapy
All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 10 years
|
10 years
|
|
|
Progression-free survival
Time Frame: 10 years
|
10 years
|
|
|
Therapy response
Time Frame: 10 years
|
Therapy Response according to RECIST Version 1.1
|
10 years
|
|
Local progression-free survival
Time Frame: 10 years
|
10 years
|
|
|
Cause-specific survival
Time Frame: 10 years
|
10 years
|
|
|
Toxicity according to NCI CTCAE
Time Frame: 10 years
|
Acute/late toxicity according to CTCAEv4.03,
June 14,2010
|
10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EORTC-QLQ-C30
Time Frame: Through study completion, at 3, 5, and 10 years
|
Patient-reported quality of life
|
Through study completion, at 3, 5, and 10 years
|
|
EORTC-QLQ-BN20
Time Frame: Through study completion, at 3, 5, and 10 years
|
Patient-reported quality of life for brain cancer patients
|
Through study completion, at 3, 5, and 10 years
|
|
EORTC-QLQ-PR25
Time Frame: Through study completion, at 3, 5, and 10 years
|
Patient-reported quality of life for prostate cancer patients
|
Through study completion, at 3, 5, and 10 years
|
|
Neurocognitive test battery
Time Frame: Through study completion, at 3, 5, and 10 years
|
Change in cognition from baseline to endpoint as measured by standardized subtests of test battery
|
Through study completion, at 3, 5, and 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Piero Fossati, MD MSc, EBG MedAustron GmbH
- Principal Investigator: Yvonne Goy, MD, EBG MedAustron GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REGI-MA-002015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ion Beam Radiation Therapy for Tumor Patients
-
NCT06132295CompletedCancer Patients | Radiation Therapy | Tattooing
-
NCT01695252CompletedPatients Referred for Routine Psychological Therapy
-
NCT01696721RecruitingPediatric Patients Treated With Radiation Therapy
-
NCT05914142CompletedSolid Tumor | Proton Therapy | Radiation Therapy
-
NCT04549246CompletedRadiation Therapy Complication | Tumor Neck | Tumor Abdomen
-
NCT00911456CompletedRadiation Therapy for Primary Breast Cancer
-
NCT07239271Not yet recruitingPatients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
-
NCT02311127CompletedPatients With Any Condition Who Need a PICC for IV Therapy
-
NCT02043470CompletedA History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)
Clinical Trials on Protons and Carbon Ions
-
NCT01811394Active, not recruitingSacral Chordoma
-
NCT02838602RecruitingMalignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
-
NCT03662373Recruiting
-
NCT04946357RecruitingSoft Tissue Sarcoma
-
NCT01182779RecruitingChordoma | Tumor | Treatment
-
NCT02672449RecruitingAdenocarcinoma of Prostate
-
NCT05733910RecruitingHead and Neck Cancer | Carcinoma, Adenoid Cystic
-
NCT05895344RecruitingCognitive Impairment | Cavernous Sinus Meningioma | Proton-therapy | Photon Radiotherapy
-
NCT05191940Recruiting
-
NCT04083937Recruiting